Merck (MRK) Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
MRK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$118.50 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.28 |
| 1 Month Change | 0% |
| 3 Month Change | 36.60% |
| 1 Year Change | -70.38% |
| 3 Year Change | -70.38% |
| 5 Year Change | 43.46% |
| Change since IPO | 200.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRK | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | 1.8% |
| 1Y | -70.4% | 41.4% | 17.5% |
Return vs Industry: MRK underperformed the Swiss Pharmaceuticals industry which returned 42.7% over the past year.
Return vs Market: MRK underperformed the Swiss Market which returned 17.1% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.3% |
Stable Share Price: MRK's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine MRK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 74,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
Merck & Co., Inc. Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | CHF 239.16b |
| Earnings (TTM) | CHF 14.41b |
| Revenue (TTM) | CHF 51.31b |
Is MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | US$65.01b |
| Cost of Revenue | US$14.82b |
| Gross Profit | US$50.20b |
| Other Expenses | US$31.94b |
| Earnings | US$18.25b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 30, 2026
| Earnings per share (EPS) | 7.39 |
| Gross Margin | 77.21% |
| Net Profit Margin | 28.08% |
| Debt/Equity Ratio | 93.7% |
How did MRK perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 10:03 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merck & Co., Inc. is covered by 49 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Emily Field | Barclays |